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TrkA receptors are well known for promoting neuronal cell survival. However, in some neuroblastic tumors,
TrkA activation can instead induce apoptosis. In this issue ofNeuron, Harel et al. identify CCM2 as amediator
of TrkA-dependent cell death, suggesting that CCM2 is a distinctive type of tumor suppressor that modulates
tyrosine kinase signaling.The Trk family of neurotrophin receptors
plays a major role in promoting neuronal
survival during development and mainte-
nance of both the central and peripheral
nervous systems. When neurotrophins
bind their cognate Trks, the activated
receptors initiate a number of signaling
pathways critical for suppressing apo-
ptosis and promoting neuronal survival,
including PI3Kinase/Akt and Ras/Raf/
MAPK. These signaling molecules partic-
ipate in the activation of a complex group
of transcription factors to promote
survival and also induce acute changes
within the cell to block apoptotic path-
ways (Reichardt, 2006).
In recent years, a growing body of liter-
ature has also documented an additional,
paradoxical role for Trk signaling: the
ability to induce cell death in the two
most common malignant solid tumors in
childhood: medulloblastoma and neuro-
blastoma (Brodeur et al., 2009; Pomeroy
et al., 1997). Both tumors arise from cells
of neural origin—neuroblastoma from the
developing sympathetic nervous system
and medulloblastoma from the neuronal
precursors in the developing cerebellum
(De Bont et al., 2008; Brodeur, 2003).
While both neuroblastomas and medul-
loblastomas are malignant tumors, the
biological and clinical behavior of each
type of tumor is remarkably heteroge-
neous. In neuroblastoma, some tumors
can undergo spontaneous regression,
while others instead progress to extensive
metastatic disease. The Trk family of
neurotrophin receptors plays critical roles
in determining this behavior. Neuroblas-
tomas expressing TrkA are biologically
favorable and prone to spontaneous re-
gression or differentiation, whereas TrkB-
expressing tumors are very aggressiveand often fatal (Brodeur et al., 2009). In
medulloblastoma, TrkC is a positive prog-
nostic indicator, as the activated receptor
can induce tumor cell apoptosis (Kim
et al., 1999). Whereas the signaling path-
ways of neurotrophin induction of cell
survival and differentiation are well known,
the mechanism by which Trk receptor
tyrosine kinases induce cell death in these
cancers is far less understood.
In this issue of Neuron, Harel et al.
(2009) for the first time shed some light
on the molecular mechanism underlying
the phenomenon of TrkA-induced cell
death in pediatric neuroblastic tumors.
During a screen for downstream effectors
of neurotrophin signaling, the authors
identified CCM2, the protein product of
the cerebral cavernous malformation 2
gene, as an interactor of TrkA. CCM2
caused extensive cell death when ex-
pressed in cells that also express TrkA,
and this effect requires the presence of
both TrkA and CCM2. Surprisingly, cell
death induction was selective for TrkA
and was not seen when CCM2 was coex-
pressed with TrkB or TrkC, even though
the cytoplasmic domain of the Trk family
is 70% conserved.
How is it possible that CCM2 binds all
three Trks but only induces death sig-
naling upon binding TrkA? To address
this question, Harel et al. used TrkA dele-
tion mutations to identify the CCM2 inter-
action site as residues 465–484 in the
juxtamembrane domain, a region of the
receptor previously reported to be re-
quired for recycling and dynein interaction
(Chen et al., 2005; Yano et al., 2001).
Furthermore, when the juxtamembrane
TrkA sequence was swapped into TrkB,
this region does confer on TrkB the ability
to cause CCM2-dependent death. It isNeuron 63, Simportant to note that although there is
no tyrosine in the CCM2-binding TrkA
sequence, the kinase activity of TrkA is
needed for death induction.
To understand how TrkA-CCM2 inter-
actions induce cell death, Harel et al.
analyzed the domain structure of CCM2.
The CCM2 protein contains two domains:
the N-terminal PTB (phosphotyrosine
binding) domain and the C-terminal death
domain, designated the Karet domain (for
the Hebrew word, which means to sever,
describing an unusual form of biblical
sanction). While the PTB domain binds
the juxtamembrane domain of TrkA, the
Karet domain is also required to execute
TrkA-CCM2-mediated cell death. Indeed,
when the PTB domain was replaced with
the Shc-PTB domain (which binds all
three Trks), the new construct was able
to induce apoptosis when coexpressed
with TrkA, TrkB, or TrkC. Together, these
data indicate that both regions of CCM2
are required for death signaling: the PTB
domain provides specificity for binding
to TrkA, and the Karet domain determines
death signaling.
During development, TrkA and its
cognate ligand NGF (nerve growth factor)
promote survival. Pediatric neurogenic
tumors are the only clearly identified para-
digm wherein TrkA promotes death. In
order to determine the biological signifi-
cance of the CCM2/TrkA interaction,
Harel et al. next downregulated endoge-
nous CCM2 in TrkA-expressing medullo-
blastoma (MB) and neuroblastoma (NB)
cell lines. In both cell lines, downregula-
tion of CCM2 by specific shRNA signifi-
cantly rescued cells from TrkA-induced
death. Thus, endogenous CCM2 is a key
mediator of TrkA-dependent cell death in
pediatric tumors of neural origin.eptember 10, 2009 ª2009 Elsevier Inc. 559
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CCM2 is critical for TrkA-mediated apo-
ptosis in tumors, the authors analyzed
expression levels from 478 pretreatment
neuroblastoma samples from patients at
all ages and stages. They found that
CCM2 and TrkA are coexpressed in
neuroblastoma, highly correlated with
one another, and both of them are corre-
lated to improved prognosis, but not inde-
pendently. No statistically significant cor-
relation was found between expression
levels and outcome for TrkB, TrkC, p75,
CCM1, and CCM3.
Together these results establish CCM2
as a first molecular link between TrkA
activation and cell death induction in
pediatric tumors. The importance of this
interaction was demonstrated for neuro-
blastoma biology. It will be very interesting
to analyze CCM2 expression data in
medulloblastoma and determine whether
the same correlations hold true there. If
so, another tyrosine kinase might be
involved in CCM2-mediated death induc-
tion in medulloblastoma, as TrkC is appar-
ently not able to induce death signaling
with CCM2.
As the work by Harel et al. clearly shows
evidence for CCM2 as a proapoptotic
molecule in pediatric tumors, it will be
very important to understand the molec-
ular mechanisms whereby the Karet
domain leads to death induction. CCM2
can interact with CCM3, another CCM
gene widely expressed in the nervous
system, and/or CCM1 (Zawistowski
et al., 2005; Voss et al., 2007). A ternary
complex consisting of CCM2, CCM1,
and MEKK3 was shown to activate p38
mitogen-activated protein kinase sig-
naling (Zawistowski et al., 2005). Another
recent work by Chen et al. (2009)
suggests that CCM3 can also induce
apoptosis when overexpressed in endo-
thelial cells. It is intriguing to speculate560 Neuron 63, September 10, 2009 ª2009 Ethat CCMs binding to different receptor
tyrosine kinases or functioning as scaf-
folds in complexes could induce cell
death in different tumors. As the func-
tional interaction site on TrkA is a specific
segment of the juxtamembrane domain
implicated in receptor internalization and
recycling (Chen et al., 2005), another
intriguing speculation is that CCM2
binding to this region could manipulate
Trk’s endocytic trafficking and thereby
switch TrkA signaling from life to death.
A full understanding of CCM2 and its
role in signaling and trafficking remains
to be developed in future experiments.
Investigating the mechanisms that
regulate CCM2-dependent death will
also be an important extension of the
present study. Harel et al. demonstrated
that CCM2 binding is unaffected by the
state of TrkA phosphorylation, and the
juxtamembrane domain does not even
have a tyrosine residue. Consistent with
this fact, the authors did not see a change
in death induction upon the addition of
the TrkA ligand NGF. However, death in-
duction still requires an active Trk kinase
domain. Taken together, these data indi-
cate that TrkA kinase is necessary for
death induction, but does not function in
the traditional ligand-dependent manner.
Hence, there must be additional steps in
pediatric tumor responses that require
the kinase and switches TrkA survival
signaling to death signaling. As CCM2
has been implicated in the interactions
of neural cells with blood vessels, it is
intriguing to speculate that some aspect
of neurovascular crosstalk may function
in this switch.
In summary, Harel et al. provide
compelling evidence that CCM2 links
TrkA to cell death induction in neuroblas-
toma. This work is especially valuable, for
it is the first explanation of the fact that
Trks are good prognostic factors in neuro-lsevier Inc.genic pediatric tumors. CCM2 could be
seen as a novel category of tumor sup-
pressors that modulates receptor tyrosine
signaling, thereby also modulating the
malignancy grade of a given tumor. In this
light, it will be very interesting to see if
this concept can be transferred to other
tumors caused by the activation of
receptor tyrosine kinases.
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